XTL Biopharmaceuticals to Present at the 9th Annual BIO CEO & Investor Conference
08 February 2007 - 6:42PM
PR Newswire (US)
NEW YORK, February 8 /PRNewswire-FirstCall/ -- XTL
Biopharmaceuticals Ltd. (NASDAQ:XTLB)(LSE:XTL)(TASE:XTL) announced
today that Ron Bentsur, the Company's Chief Executive Officer, is
scheduled to present at the 9th Annual BIO CEO & Investor
Conference. Mr. Bentsur will present an overview of the Company
including an overview of Bicifadine, the Company's recently
in-licensed late-stage clinical compound for the treatment of
neuropathic pain. Mr. Bentsur's presentation will take place on
Wednesday, February 14th, 2007 at 3:00 pm Eastern Standard Time, at
the Waldorf Astoria Hotel in New York City. A live audio webcast of
Mr. Bentsur's presentation will be available at:
http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=XTLB&item_id=1475520
An archived version of the webcast will be available following the
conclusion of the live presentation. About XTL Biopharmaceuticals
Ltd. XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the
acquisition, development and commercialization of therapeutics for
the treatment of neuropathic pain and hepatitis C. XTL is
developing Bicifadine, a serotonin and norepinephrine reuptake
inhibitor, for the treatment of neuropathic pain. In addition, XTL
is developing XTL-2125 - a small molecule, non-nucleoside inhibitor
of the hepatitis C virus polymerase. XTL-2125 is currently in a
Phase 1 clinical trial in patients with chronic hepatitis C. XTL is
also developing XTL-6865 - a combination of two monoclonal
antibodies against the hepatitis C virus - presently in Phase 1
clinical trials in patients with chronic hepatitis C. XTL's
hepatitis C pipeline also includes several families of pre-clinical
hepatitis C small molecule inhibitors. XTL also has an active
in-licensing and acquisition program designed to identify and
acquire additional drug candidates. XTL is publicly traded on the
NASDAQ, London, and Tel-Aviv Stock Exchanges
(NASDAQ:XTLB)(LSE:XTL)(TASE:XTL). Contact: Ron Bentsur, Chief
Executive Officer Tel: +1-212-531-5960 DATASOURCE: XTL
Biopharmaceuticals Ltd CONTACT: Contact: Ron Bentsur, Chief
Executive Officer, Tel: +1-212-531-5960
Copyright
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jun 2024 to Jul 2024
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jul 2023 to Jul 2024